CN101991599A - 可使病变组织及病原体溶解消除的药物 - Google Patents

可使病变组织及病原体溶解消除的药物 Download PDF

Info

Publication number
CN101991599A
CN101991599A CN2009100420308A CN200910042030A CN101991599A CN 101991599 A CN101991599 A CN 101991599A CN 2009100420308 A CN2009100420308 A CN 2009100420308A CN 200910042030 A CN200910042030 A CN 200910042030A CN 101991599 A CN101991599 A CN 101991599A
Authority
CN
China
Prior art keywords
medicine
pathogen
sodium hydroxide
weight
dissolving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009100420308A
Other languages
English (en)
Inventor
谭国梁
谭晓雯
谭晓晴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110427188.8A priority Critical patent/CN113082046A/zh
Priority to CN2009100420308A priority patent/CN101991599A/zh
Priority to CN201510358361.8A priority patent/CN104940225A/zh
Priority to US13/392,267 priority patent/US10251925B2/en
Priority to EP10811173.3A priority patent/EP2471541B1/en
Priority to PCT/CN2010/073628 priority patent/WO2011023013A1/zh
Priority to JP2012525865A priority patent/JP2013502443A/ja
Publication of CN101991599A publication Critical patent/CN101991599A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明涉及可使病变组织及病原体溶解消除的药物，按重量计量，总份量设为100.0，其中包括氢氧化钠1.0-60.0，其余加水至100.0；或以氢氧化钾取代氢氧化钠，份量不变；或以氢氧化钠与氢氧化钾的混合物取代氢氧化钠，份量不变；还可以加入有局部麻醉作用的化合物，如丁卡因1.0；或蟾酥灵0.25-0.5；或蟾酥0.5-1.0；或薄荷醇0.5-1.0，成为复方制剂。本发明建基于民间和传统中医药，结合现代医药科学技术，对民间和传统医药中利用生石灰碱性化学性质的药理作用和临床经验进一步挖掘和发展，可使病变组织及病原体实时溶解消除，疗效快、效果显著、副作用小，具有较好的推广应用前景。

Description

可使病变组织及病原体溶解消除的药物
技术领域
本发明属于药物技术领域，具体属于外治赘生物、恶肉、疽疮、瘿瘤疣子、痛疥瘙癣的药物，涉及可使病变组织及病原体溶解消除的药物。
背景技术
生石灰又称石灰或氧化钙，在我国现存最早药物学专著《神农本草经》中记载：“主疽疡疥瘙，热气恶性疮，癞疾死肌堕眉，杀痔虫，去黑子息肉。”汉末《名医别录》：“疗髓骨疽。”唐代甄权《药性论》：“治痛疥，蚀恶肉，不入汤服，止金疮血，和鸡子白，败船茹甚良。”宋初《日华子本草》：“生肌长肉，止血，并主白癜、疬疡、瘢疵等，疗冷气、痔瘘疽疮，瘿瘤疣子”。生石灰历代广泛用于燥湿、杀虫、止血、定痛、蚀恶肉、治疥癣、湿闪、创伤出血、汤火烫伤、痔疮、脱肛、赘疣，具有较好的疗效。
发明内容
本发明建基于民间和传统中医药，并对民间和传统医药中利用生石灰之碱性化学性质的药理作用和临床经验继承和发展，提供一种可使病变组织及病原体实时溶解消除的药物。
本发明的目的是通过采用以下技术方案来实现的：
可使病变组织及病原体溶解消除的药物，所述药物按重量计量，总份量设为100.0，其中包括氢氧化钠1.0-60.0，其余加水至100.0；
或以氢氧化钾取代氢氧化钠，份量不变；
或以氢氧化钠与氢氧化钾的混合物取代氢氧化钠，份量不变。
本发明所述药物可以加入有局部麻醉作用的化合物，例如丁卡因1.0；
或，蟾酥灵0.25-0.5；
或，蟾酥0.5-1.0；
或，薄荷醇0.5-1.0；
或，赋形剂卡波姆(941)0-0.5，成为复方制剂。
本发明所述药物可以加入：薄荷醇0-1.0、异甘草素0-0.5、黄芩素0-0.5、小檗碱0-0.5、大黄素0-0.5、赋形剂卡波姆(941)0-0.5，成为复方制剂。
本发明所述药物可以加入磨成微粉的如下中药或中药材的热水抽提物：
薄荷0-1.0、甘草0-3.0、黄芩0-3.0、黄柏0-3.0、大黄0-3.0、赋形剂卡波姆(941)0-0.5，成为复方制剂。
本发明的有益效果是：本发明建基于民间和传统中医药，结合现代医药科学技术，对民间和传统医药中利用生石灰之碱性化学性质的药理作用和临床经验进一步挖掘和发展；本发明可使病变组织及病原体实时溶解消除，疗效快、效果显著、副作用小，具有较好的推广应用前景。
具体实施方式
可使病变组织及病原体溶解消除的药物，按重量计量，总份量设为100.0，其中包括氢氧化钠1.0-60.0，其余加水至100.0；
或以氢氧化钾取代氢氧化钠，份量不变；
或以氢氧化钠与氢氧化钾的混合物取代氢氧化钠，份量不变。
氢氧化钠、氢氧化钾能够溶解蛋白质，其适当的浓度可以实时溶解消除由蛋白质组成的各种病变组织及病原体，这是本发明的根据。
本发明药物制剂，也可以加入有局部麻醉作用的化合物，例如丁卡因1.0；或蟾酥灵0.5；或蟾酥0.75；或薄荷醇1.0；制成为复方制剂。使其用于治疗疾病时，可以在无痛或轻痛中实施。本发明也可以加赋形剂卡波姆(941)0-0.5，使其成为复方制剂。
本发明药物制剂，也可加入中药等有效成分，例如：薄荷醇0-1.0、异甘草素0-0.5、黄芩素0-0.5、小檗碱0-0.5、大黄素0-0.5、赋形剂卡波姆(941)0-0.5，使其成为复方制剂。
本发明也可加入磨成微粉的中药或热水抽提物，例如：薄荷0-1.0、甘草0-3.0、黄芩0-3.0、黄柏0-3.0、大黄0-3.0，以及赋形剂卡波姆(941)0-0.5，使其成为复方制剂。
甘草(甘草酸、异甘草素)有抗菌、抗病毒、抗肿瘤、抗炎、及免疫调节作用；大黄(大黄素)有抗菌抗病毒消炎及抗肿瘤作用；黄芩(黄芩素)抗菌抗病毒抗过敏抗癌作用；黄柏(小檗碱)有抗菌抗癌作用。以上这些中药或其有效成份与氢氧化钠或氢氧化钾组成复方制剂，可以增强药物的疗效。
实施例1
称为“可使病变组织及病原体溶解消除的药物1号制剂”，又名溶疣消赘膏。
其配方配比是(重量份)：氢氧化钠20.0、丁卡因1.0，余量加水至100.0。
本品特征为具有超卓的立即溶解消除病变组织及病原体之作用，适用于***(CA)、***、皮肤癌、各种组织和器官之息肉、癌前病变、结节性痒疹、墨痣、鸡眼、寻常疣、皮赘的治疗。
治疗***，鬼臼毒素Podophyllotoxin，为世界卫生组织及中国国家***推荐的首选药物。美国施泰福药厂产品称WARTREC疣敌，中国贵州汉方制药称疣迪，其主要成分都是鬼臼毒素。药品说明书：局部外用，涂搽于患处：早晚各二次，连用3天至疣体发白，停药观察4天，共7天为一疗程。疣体未消退者进行第二疗程。总计不超过三疗程(21天)。
应用本发明“可使病变组织及病原体溶解消除的药物1号制剂”，在治疗男性***内板(包括尿道)、***、***(包括官颈、***)等部位湿润多汁的***，以棉签涂药，其效果如烈火溶冰，花生米大之疣粒，十数分钟之内，迅速溶化成半透明的胶汁，剩余相当于疣体三分一大之黑色内核(血根团)，此内核实乃CA组织之真皮内增生、扩张的毛细血管球团，受药物之作用，变黑并缩细。抹净半透明胶汁，再搽药数次，黑色的血根团继续被溶化、萎缩，或脱除，整个过程不过三十分钟左右，伤口实时缩细，数日可愈合，细小疣粒，以竹制牙签搽药，较为准确，二、三分钟可溶化根除。
实施例2
称为“可使病变组织及病原体溶解消除的药物2号制剂”，又称疱疹疮毒立消膏。
其配方组成：甘草3.0、黄芩3.0、黄柏3.0、大黄1.0、薄荷脑1.0、氢氧化钠2.5、蟾酥1.0，加赋形剂卡波姆(941)0.25、加水至100.0。
成份中之甘草、黄芩、黄柏、大黄、蟾酥、薄荷脑，乃磨成200目之粉末。
本品可用于***，在应用“可使病变组织及病原体溶解消除的药物1号制剂”，化除肉眼所见的大小疣粒后，应用本品“可使病变组织及病原体溶解消除的药物2号制剂”，广泛涂搽患区及周围区域，处理CA之「亚临床」病区，溶解消除细微的病灶及病原体HPV病毒，减少再发机会。五至二十分钟后，以蒸馏水棉球抹去药物，结束治疗。
可使病变组织及病原体溶解消除的药物1号制剂及2号制剂联合应用，以这样的药物制剂，如此快速的实时溶解消除***(包含疣内HPV病毒)，国内外文献未有同样记载。
每次复诊，以数码相机照相，输入计算机检查，放大10-50倍，观察是否仍存「亚临床」病变，以便继续处理。
“可使病变组织及病原体溶解消除的药物2号制剂”，适用于性病疱疹、带状庖疹、各期酒渣鼻、炎性痤疮、各期慢性子***、化脓性汗腺炎、脓肿、痈疖、炎性肉芽肿、环状肉芽肿、疥疮、孢子丝菌病。此方剂的特征在于：若掌握恰当的搽药次数和持续时间，可对患病组织有高度选择作用而不伤及正常组织。
例如***生殖器疱疹，带状疱疹，于涂搽本品后数分钟，疼痛即减，患处毒液渐被吸出，十数分钟疼痛消失。疱疹消失时间：最快5分钟，最慢48分钟，平均18.77分钟。结痂愈合时间：最快17小时，最慢38小时，平均26.11小时。这样好的疗效，国内外文献未见记载。
例如治疗各期酒渣鼻、炎性脓肿痤疮，把药剂涂布患区，数分钟后即见病变组织开始溶解、脓液毒汁渗出、病变缩细、抹去溶解渗液。如此再搽药1-2次，病损实时消除，渗出停止。翌日结痂，10-14天痂脱，重现粉红细嫩新皮。严重的酒渣鼻如鼻赘期，可分区、多次用药，由表及里，溶化、清除赘生物。目前国内外文献尚未有用这种药物方剂和方法，治疗酒渣鼻和颜面炎性痤疮；其它的治疗酒渣鼻和炎性脓肿痤疮的药物和方法，也未取得如此快速疗效。
实施例3
称为“可使病变组织及病原体溶解消除的药物3号制剂”，其配方：甘草酸1.0、黄芩素1.0、小檗碱1.0、大黄素1.0、薄荷脑1.0、氢氧化钠(或氢氧化钾)4.0、蟾酥0.5，加赋形剂卡波姆(941)0.25、加水至100.0。
本品适用于扁平疣、皮肤结核、结核样型麻风、老人斑、毛囊炎。
治扁平疣、***、老人斑、毛囊炎，宜用牙签或小棉花签准确涂药，见皮疹变焦黑，即可抹去药液。对于用抗生素治疗数月开始见效的皮肤结核、结核样型麻风，把本品涂布于皮疹上，数分钟毒汁渗出，抹去药物，即见皮损萎缩，一周后视情况再次涂药治疗，可明显缩短疗程；也适用于治疗神经性皮炎、玫瑰糠疹、体癣、足癣。
本品以蒸馏水或矿泉水稀释1-10倍外用，洗、涂布于小面积I-II度烧伤或烫伤，能迅速止痛、去热毒、消水疱、防感染。
实施例4
称为“可使病变组织及病原体溶解消除的药物4号制剂”，其配方：
氢氧化钠(或氢氧化钾)30.0，加蒸馏水至100.0。
本品外搽，可用于溶解灰指(趾)甲，也可用溶解硬皮、死皮。
本制剂也可于患者局部病变组织相对细小、长在疼痛较不敏感部位；在患者已作全身麻醉或其病变组织已在局部麻醉的情况下，本制剂可用于局部涂布溶解范围较广深、疼痛较敏感的病变组织，作快速、深彻的溶解。其用途用法可参考实施例1“可使病变组织及病原体溶解消除的药物1号制剂”的用途用法。
本发明还可以有其它的实施例，在此不一一列举。本发明的内容不仅仅限于实施例，凡属于本发明权利要求保护内容，均落入本发明的保护范围内。

Claims (4)

1.一种可使病变组织及病原体溶解消除的药物，其特征是：所述药物按重量计量，总份量设为100.0，其中包括氢氧化钠1.0-60.0，其余加水至100.0；
或以氢氧化钾取代氢氧化钠，份量不变；
或以氢氧化钠与氢氧化钾的混合物取代氢氧化钠，份量不变。
2.根据权利要求1所述的可使病变组织及病原体溶解消除的药物，其特征是：所述药物可以加入有局部麻醉作用的化合物，例如丁卡因1.0；
或，蟾酥灵0.25-0.5；
或，蟾酥0.5-1.0；
或，薄荷醇0.5-1.0；
或，赋形剂卡波姆(941)0-0.5，成为复方制剂。
3.根据权利要求1所述的可使病变组织及病原体溶解消除的药物，其特征是：所述药物可以加入：薄荷醇0-1.0、异甘草素0-0.5、黄芩素0-0.5、小檗碱0-0.5、大黄素0-0.5、赋形剂卡波姆(941)0-0.5，成为复方制剂。
4.根据权利要求1所述的可使病变组织及病原体溶解消除的药物，其特征是：所述药物可以加入磨成微粉的如下中药或中药材的热水抽提物：
薄荷0-1.0、甘草0-3.0、黄芩0-3.0、黄柏0-3.0、大黄0-3.0、赋形剂卡波姆(941)0-0.5，成为复方制剂。
CN2009100420308A 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物 Pending CN101991599A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202110427188.8A CN113082046A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
CN2009100420308A CN101991599A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
CN201510358361.8A CN104940225A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
US13/392,267 US10251925B2 (en) 2009-08-24 2010-06-07 Pharmaceutical composition for dissolving and eliminating pathological tissues and pathogens and its usage
EP10811173.3A EP2471541B1 (en) 2009-08-24 2010-06-07 Medicine for dissolving and eliminating wart and excrescence consisting of protein and its uses
PCT/CN2010/073628 WO2011023013A1 (zh) 2009-08-24 2010-06-07 可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途
JP2012525865A JP2013502443A (ja) 2009-08-24 2010-06-07 タンパク質からなる疣と新生物を溶解して除去できる薬物及びその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009100420308A CN101991599A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110427188.8A Division CN113082046A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
CN201510358361.8A Division CN104940225A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Publications (1)

Publication Number Publication Date
CN101991599A true CN101991599A (zh) 2011-03-30

Family

ID=43627218

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110427188.8A Pending CN113082046A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
CN2009100420308A Pending CN101991599A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物
CN201510358361.8A Pending CN104940225A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110427188.8A Pending CN113082046A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510358361.8A Pending CN104940225A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Country Status (5)

Country Link
US (1) US10251925B2 (zh)
EP (1) EP2471541B1 (zh)
JP (1) JP2013502443A (zh)
CN (3) CN113082046A (zh)
WO (1) WO2011023013A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247335A (zh) * 2011-06-02 2011-11-23 江苏省中医药研究院 一种蟾毒灵干粉吸入剂及其制备方法、应用
CN108295088A (zh) * 2018-04-18 2018-07-20 董新声 一种用于寻常疣的外用药及使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319637B1 (en) 2015-07-10 2022-11-09 Infectopharm Arzneimittel und Consilium GmbH Use of potassium hydroxide in the treatment of actinic keratosis
GB201512410D0 (en) * 2015-07-16 2015-08-19 Univ Plymouth Method
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
EP3691688B1 (en) 2017-10-06 2021-12-08 Laboratorio Reig Jofré, S.A. Hydrogel compositions for the treatment of molluscum contagiosum
CN107898856A (zh) * 2017-11-27 2018-04-13 内蒙古东达獭兔循环产业研究院 一种治疗兔子真菌病的药物组合物、兔子饲料及制备方法
CN110025739A (zh) * 2019-06-05 2019-07-19 袁宗生 一种治疗瘊子、扁平疣的组合物及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055660A (en) * 1974-06-26 1977-10-25 Meierhenry Dwight W Treatment for warts
JPS62207212A (ja) * 1986-03-08 1987-09-11 Nippon Haipotsukusu:Kk 抗アレルギ−剤
US5433950A (en) * 1990-05-07 1995-07-18 Schering-Plough Healthcare Products, Inc. Flexible collodion compositions
CN1093576A (zh) * 1993-12-24 1994-10-19 肖林章 消痣膏及其配制方法
CN1065430C (zh) * 1997-09-20 2001-05-09 侯润安 一种治疣糊剂
CN1103230C (zh) * 1999-03-25 2003-03-19 项观相 一种治疗黑痣、雀斑、老年斑、扁平疣的外用膏剂及其制备方法
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US7572469B2 (en) * 2002-04-15 2009-08-11 Tetsuo Santo Therapeutic lotion for dermatitis
CN1209152C (zh) * 2003-03-31 2005-07-06 刘振杰 一种除疣痣组合物及其制备方法
US20080031929A1 (en) * 2005-07-28 2008-02-07 Baggett Richard W Liquid bandage
KR100812596B1 (ko) * 2006-12-15 2008-03-13 바이오스펙트럼 주식회사 천연 유래 화합물을 포함하는 피부보호 조성물
CN101433617B (zh) * 2007-11-13 2014-12-17 谭国梁 一种溶疣消赘清毒膏
WO2009082511A1 (en) * 2007-12-20 2009-07-02 Elc Management Llc Methods and compositions for treating skin
WO2009097512A1 (en) * 2008-02-01 2009-08-06 Innovative Drug Discovery Inc. Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247335A (zh) * 2011-06-02 2011-11-23 江苏省中医药研究院 一种蟾毒灵干粉吸入剂及其制备方法、应用
CN108295088A (zh) * 2018-04-18 2018-07-20 董新声 一种用于寻常疣的外用药及使用方法

Also Published As

Publication number Publication date
CN113082046A (zh) 2021-07-09
WO2011023013A1 (zh) 2011-03-03
EP2471541B1 (en) 2023-05-10
US10251925B2 (en) 2019-04-09
EP2471541A1 (en) 2012-07-04
EP2471541A4 (en) 2013-03-20
JP2013502443A (ja) 2013-01-24
US20120189718A1 (en) 2012-07-26
CN104940225A (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
CN101991599A (zh) 可使病变组织及病原体溶解消除的药物
WO2006076844A1 (fr) Medicament chinois traditionnel destine a traiter les blessures resultant de chutes, rhumatisme et ostealgie et son procede de fabrication
CN101433617B (zh) 一种溶疣消赘清毒膏
CN1327875C (zh) 治疗慢性***的中药制剂及其制备方法
CN102973750A (zh) 治疗风湿、类风湿以及痛风性关节炎和颈椎病的中药
CN104623607B (zh) 一种治疗风湿类风湿病的中药组合物
CN103520439A (zh) 一种治疗热毒蕴结型慢性骨髓炎的中药及其制备方法
CN106039109A (zh) 防治寒湿阻络型的类风湿性关节炎的中药药酒
CN102885961B (zh) 一种治疗风湿性关节炎、类风湿性关节炎的药物及其制备方法
CN101530516B (zh) 一种治疗阑尾炎的中药
CN102416064A (zh) 治疗已破溃冻疮的药物
CN104857089B (zh) 一种治疗风湿和类风湿性关节炎的药液及其制备方法
CN100493544C (zh) 一种治疗风湿病的外用药
CN108619427A (zh) 一种预防治疗痛风性关节炎的祛痛降酸药茶
CN108686102A (zh) 一种治疗痛风的中药组合物
CN114392331A (zh) 一种含蕲蛇治疗痛风性关节炎的制剂
CN102920874B (zh) 治疗感染的膏药
CN102784344B (zh) 一种治疗肺结核的中药制剂
CN101491599B (zh) 一种化输尿管结石的复方石韦金钱草汤
CN104887702A (zh) 一种治疗皮肤外伤及溃烂的中药组合物及其制备方法
CN105999131B (zh) 一种治疗慢性***炎的外用壮药组合物
CN104825919B (zh) 一种治疗艾滋病发热的中药液
CN105412315A (zh) 一种治疗扁桃体及***炎症的中药组合物膏剂
CN105125995A (zh) 一种治疗风湿痹痛的中药组合物
CN105079482B (zh) 一种治疗严重褥疮伴感染的中药外用凝胶剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110330